February 2026 Research Update

This month, treatment-related papers were mostly single-patient reports, so they offer early signals rather than clear answers. Across these cases, patients with difficult or complicated pulmonary alveolar proteinosis (PAP) sometimes improved when therapy targeted the underlying immune driver, reduced a suspected trigger, or changed how lung surfactant (the material that builds up in PAP) is handled. At the same time, the reports also showed that improvement may not last without ongoing control of the cause, and results can differ widely from one person to another. [1] [2] [3]

In one refractory autoimmune PAP case, a rituximab-based approach (an immune-targeting antibody treatment) plus other therapies was followed by improved symptoms and chest imaging, with anti-GM-CSF antibody levels falling alongside clinical improvement. When rituximab maintenance was spaced out, disease came back, which matched the idea that ongoing immune activity was still present. This case also noted recurrent Mycobacterium avium complex infections during the course, reminding readers that immune-targeting regimens can coincide with infection complications in some situations. [1]

Two other cases highlighted potentially reversible contributors in specific settings. In a person with dermatomyositis-associated lung disease who developed secondary PAP while taking tofacitinib (a JAK inhibitor), stopping tofacitinib was followed by rapid clinical and CT improvement, and anti-GM-CSF antibodies were negative. In a separate autoimmune PAP case, starting pitavastatin (a cholesterol-lowering statin) was followed by marked improvements over about a year, but the patient later relapsed around 2 years after starting it. [2] [3]

For patients and caregivers, these reports add to the picture that PAP can sometimes improve when the underlying immune problem is controlled, when a medication-related trigger is removed in secondary PAP, or when pathways related to fat and surfactant handling are altered. Because each report describes only 1 person, it is not possible to know how often these responses happen or who might respond similarly. The most practical takeaway is about understanding variability: some improvements were substantial, but one case showed relapse when maintenance was relaxed and another showed relapse after a period of remission, so durability remains uncertain. [1] [2] [3]

Two human studies added support for the idea that measurable substances linked to lung injury and cell cleanup problems may help reflect how severe PAP is. One small study in autoimmune PAP found that extracellular DNA in lung wash fluid rose alongside signs of worse gas exchange, fitting with a picture of impaired clearing of dying cells in the lungs. A large hospital dataset found that KL-6, a blood marker of lung cell injury, was very high in the PAP subgroup compared with other interstitial lung diseases, suggesting it may flag heavier disease burden in that context. [4] [5]

In the autoimmune PAP study, bronchoalveolar lavage fluid contained more cell debris and higher levels of extracellular double-stranded DNA than in people with other interstitial lung diseases. The same samples showed that alveolar macrophages (the lung's cleanup cells) had reduced uptake of dying cells, and higher DNA levels tracked with worse oxygen transfer measures. This links a simple measurement in lung fluid to a biological explanation for why material may build up in PAP. [4]

In the China hospital cohort, KL-6 levels differed across interstitial lung disease types, and the PAP subgroup had the highest reported median KL-6 level. The study also mapped how different ILD categories varied by region and over time, but for PAP the main point was how extreme KL-6 elevations can be in this diagnosis within that hospital-based dataset. Because the report was not focused solely on PAP, it does not show how KL-6 changes over time in PAP or how it compares with other PAP-specific tests. [5]

These studies mainly add understanding rather than changing anything immediately for patients. They support the idea that PAP severity may be reflected by markers of lung cell injury in blood (KL-6) and by markers of poor lung cleanup in lavage fluid (extracellular DNA), which could matter in the future for tracking disease activity or research trials. Important uncertainties remain, including how these measures perform in larger PAP-only groups, whether they reliably change with improvement or relapse, and whether they add information beyond existing monitoring tools. [4] [5]

This month included two mouse studies that push the science in complementary directions: one explored a new inhaled way to deliver GM-CSF using mRNA, and the other identified a gene loss that can produce a PAP-like buildup by disrupting how lung macrophages handle lipids. Together they reinforce a central theme in PAP research, that alveolar macrophage function is a key bottleneck for clearing surfactant and lung lipids. These are early-stage findings and do not predict how people will respond, but they help sharpen targets for future therapies and models. [6] [7]

In one mouse study, nebulized lipid nanoparticles carrying GM-CSF mRNA reached alveolar macrophages and reduced surfactant protein buildup in the lungs, in some comparisons more than recombinant GM-CSF. The treatment also shifted macrophage signals toward an IL-10-related pattern, and the report described limited short-term inflammatory changes aside from early IL-5 increases. The main meaning is proof-of-concept that inhaled mRNA delivery to the key lung cells is possible in animals, with many open questions about dosing, durability, and long-term safety. [6]

In a separate mouse model, ARF-deficient mice developed lipid and protein accumulation in the air spaces and foamy alveolar macrophages, resembling pulmonary alveolar proteinosis. The study linked this to increased lipid uptake and reduced lipid export in macrophages, along with fewer alveolar macrophages and early changes in lung stiffness. This helps expand the set of biological pathways that can lead to a PAP-like state, which may be useful for understanding secondary forms of PAP and for testing future treatments in models. [7]

For patients, these findings are mainly research and not ready for clinical use. They strengthen the idea that restoring how alveolar macrophages process surfactant and lung lipids is central to improving PAP, whether by delivering GM-CSF in a new way or by understanding genes and pathways that disrupt macrophage balance. What remains uncertain is how well these mouse results translate to humans, and whether the newer delivery approaches will prove safe and effective in longer studies and eventually in clinical trials. [6] [7]

One case report added a reminder that PAP-like material in the lungs can appear during severe infections, which can complicate diagnosis when symptoms worsen quickly. In this report, lung wash testing showed aggregates consistent with PAP during a rapidly progressive respiratory illness tied to flea-borne typhus. The main addition this month is the possibility that PAP can be a pulmonary complication in rickettsial infection, at least in rare situations. [8]

In the reported patient, imaging showed widespread hazy lung changes, and bronchoalveolar lavage revealed acellular eosinophilic aggregates consistent with PAP while serology supported flea-borne typhus. The clinical course progressed to severe acute respiratory distress, showing how quickly respiratory failure can develop in some infectious contexts where PAP-like findings are present. Because this is a single case, it is not clear how often this occurs, or whether the same pattern would be seen in other rickettsial infections. [8]

This case mainly adds awareness rather than a general lesson for most people living with PAP. It suggests that, in rare settings, PAP-like findings may show up during a severe infection and be part of a fast-moving lung illness, which could affect how doctors interpret lung imaging and lavage results in that moment. The uncertainty is large because only 1 person was reported, so it does not establish how common this complication is or how it should be managed in general. [8]